Twilight of NIH Drug Discovery Program Will Mean Even Slimmer Pickings for AIDS Therapeutic Pipeline Farewell, 'Fishing Expeditions' In our national HIV/AIDS effort we must insure that all stages in the development of therapies are supported. These stages include basic…
Vaccine Victory (Of Sorts), Or "Yes, Only Not In My Backyard." -- Genentech's Don Francis Has the Last Word. WHO gave the green light to vaccine prevention studies in developing countries with the very products judged by US officials to…
Ten Years On, Feckless IL-2 Researchers Plod Ahead, Certain Of Success Tenuous Balance HIV disease is characterized by the progressive depletion of CD4+ T-cells, and the cytokine IL-2 (a.k.a. "T-cell gowth factor") is the hormone-like peptide that allows one T-cell…
Dazed and Confused, ACTG "Re"-Competitors Ready Themselves For The 1996-2001 Funding Cycle Sixty Million Dollar Pie Back in 1981, when this plague that has now ravaged the planet and forever changed the way its people see sex made its grisly…
Brouhaha Over Human Chorionic Gonadotropin (hCG) Yields, Again, To Sober Realism Vesnarinone In the Wings Per usual, AIDS related malignancies were the ugly step-sister of the X International Conference on AIDS, with only one formal session and a handful of…
Public Hearings At FDA Juxtapose Old Cries of Access With Those of Integrity, Accountability Paean to the 'Greater Good' The FDA recently held hearings about the perceived shortcomings of its Accelerated Approval program. Among many soul-searching and provocative addresses delivered…
Improved Clinical Outcomes Wrought By Immunosuppressive Medicine and Second-Rate Immune Responses - Where Will It All End? When Good 'Trapping' Is Bad Craig Sterritt has been tracking down the latest AIDS pathogenesis research - in addition to his project researching…
Research Paper Details Advances, Obstacles In The Treatment of Kaposi's Sarcoma Unwarranted Nihilism TAG's Michael Marco and APLA's Marty Majchrowicz debuted their joint collaboration, "The KS Project Report: Current Issues in Research and Treatment of Kaposi's Sarcoma" at the X…
Shot Down Early On, Merck Scientists Test Higher Doses And Combinations, Hoping for Success Production Problems Loom The Merck protease inhibitor, L-524, has recently begun to generate a lot of talk. The data from the first controlled study in 70…
Yokohama Roundtable Examines Treatment Quandary Facing Patients, Clinicians Alike Burning Last Lightbulb At Noon Mark Harrington was invited to speak at the Thursday afternoon roundtable discussion in Yokohama, "When To Start Antiretroviral Treatment." The session was moderated by Australia's BW…